

**Multiple Choice Assessment Questions**

1. In what age group is the asthma incidence rate the highest?
  - a. Elderly
  - b. Children
  - c. Adult
  - d. All are equal
  
2. Environmental risk factors for the development of asthma include:
  - a. Socioeconomic status
  - b. Allergen exposure
  - c. Exposure to secondhand tobacco smoke at infancy
  - d. All the above
  
3. What is a risk factor for early recurrent wheezing associated with viral infections?
  - a. Female gender
  - b. Male gender
  - c. High birth weight
  - d. Premature birth
  
4. What is a common symptom of asthma?
  - a. Wheezing
  - b. Whistling
  - c. Full breaths
  - d. Snoring
  
5. What is the value that is measured by spirometry?
  - a. Residual volume
  - b. Total lung capacity
  - c. Functional residual capacity
  - d. Forced expiratory volume
  
6. What drug therapy should be available to ALL asthma patients (intermittent and persistent)?
  - a. Low dose ICS
  - b. PRN SABA
  - c. LABA
  - d. Leukotriene Antagonist

7. What is the most appropriate place in therapy for long-acting beta-agonists?
  - a. As monotherapy
  - b. As rescue therapy
  - c. In combination with ICSs
  - d. In combination with cromolyn
  
8. Theophylline use is can be limited by which of the following?
  - a. The need to constantly monitor serum levels
  - b. A narrow therapeutic index
  - c. Numerous drug and disease interactions
  - d. All of the above
  
9. Tolerance to therapeutic effectiveness has been demonstrated by which of the following therapies?
  - a. SABAs
  - b. LABAs
  - c. Cromolyn
  - d. A & B
  
10. Which of the following drug classes are not considered primary therapy of asthma and are more often used as alternatives when control of the asthma cannot be achieved by first-line regimens:
  - a. SABAs
  - b. ICSs
  - c. Leukotriene modifiers
  - d. Theophylline/methylxanthines
  - e. C & D
  
11. When can a patient expect to begin to see an improvement in asthma symptoms when using inhaled corticosteroids (ICSs)? When can they expect maximum improvement?
  - a. 4 to 8 weeks; 1 to 3 months
  - b. 1 to 2 weeks; 4 to 8 weeks
  - c. 1 to 2 weeks; 6 months
  - d. 4 to 8 weeks; 6 months
  
12. Which of the following is true concerning the use of inhaled corticosteroids for asthma?
  - a. They are all pregnancy category D or X
  - b. The inhaled corticosteroids (ICSs) cause hypothalamic-pituitary-adrenal axis (HPA) suppression to a greater degree than oral systemic corticosteroids

- c. The inhaled corticosteroids (ICSs) are considered the preferred long-term therapy to control asthma
  - d. The inhaled corticosteroids (ICSs) should be used for the relief of acute bronchospasm
13. Which of the following leukotriene modifiers requires monitoring of alanine aminotransferase enzymes (ALTs)?
- a. Zileuton
  - b. Zafirlukast
  - c. Montelukast
  - d. Both A and B
14. What is the appropriate dose of montelukast in patients aged 15 and older with asthma?
- a. 5 mg/day
  - b. 4 mg/day
  - c. 10 mg /day
  - d. 20 mg/day
15. Omalizumab is approved for use in which of the following patients?
- a. Chronic asthma in patients >12 years old not well controlled on oral or inhaled corticosteroids
  - b. Patient with asthma exacerbations
  - c. Chronic asthma in patients >12 years old as add on therapy to inhaled corticosteroids
  - d. Chronic asthma in patients >12 years old as add on therapy to long acting beta agonists (LABAs)

**To receive continuing education credit, please note the following information:**

1. Complete the participant information in the spaces provided. Use **BLUE** ink only.
2. Mail the completed form for scoring to the address listed below. The quiz must be postmarked by the expiration date. Faxed CE quizzes WILL NOT be accepted.

Mail to: **APA, 1211 Carmichael Way, Montgomery, AL 36106**

3. CE processing is free for APA members. Non-members must include a processing fee of \$20 per quiz.
4. No more than 3 quizzes will be accepted per month per individual.
5. Credit will be awarded for a passing grade of 80% or better. If you fail the exam, you may retake it once, and corrected answers must be in **RED** ink.

## Participant Information:

AL License # \_\_\_\_\_

Name \_\_\_\_\_

Address \_\_\_\_\_

City \_\_\_\_\_ State \_\_\_\_\_ Zip \_\_\_\_\_

E-mail \_\_\_\_\_

NABP e-Profile # \_\_\_\_\_

MM/DD (month/day of birth) \_\_\_\_\_

How long did it take you to read the program and complete this test?

\_\_\_\_\_ hours \_\_\_\_\_ minutes

My signature certifies that I have independently taken this CE examination.

\_\_\_\_\_

### CE Assessment Answers

Please circle your answers (one answer per question).

1.	A	B	C	D	
2.	A	B	C	D	
3.	A	B	C	D	
4.	A	B	C	D	
5.	A	B	C	D	
6.	A	B	C	D	
7.	A	B	C	D	
8.	A	B	C	D	
9.	A	B	C	D	
10.	A	B	C	D	E
11.	A	B	C	D	
12.	A	B	C	D	
13.	A	B	C	D	
14.	A	B	C	D	
15.	A	B	C	D	

### Program Evaluation - Must be completed for credit.

Please rate the following items on a scale from 1 (poor) to 4 (excellent).

1. Overall quality of the article 1 2 3 4

2. Relevance to pharmacy practice 1 2 3 4

3. Value of the content 1 2 3 4

Please answer each question, marking whether you agree or disagree.

4. This course met the learning objectives. ☐ Agree ☐ Disagree

Impact of the Activity

The information presented (check all that apply):

5. ☐ Reinforced my current practice/treatment habits

☐ Will improve my practice/patient outcomes

☐ Provided new ideas or information I expect to use

☐ Adds to my knowledge

6. Will the information presented cause you to make any changes in how you do your job? ☐ Yes ☐ No

7. How committed are you to making these changes?

(Not committed) 1 2 3 4 (Very committed)

8. Do you feel future activities on this subject matter are necessary and/or important? ☐ Yes ☐ No

Follow-Up

As part of our ongoing quality-improvement effort, we would like to be able to contact you in the event we conduct a follow-up survey to assess the impact of our educational interventions on professional practice. Are you willing to participate in such a survey? ☐ Yes ☐ No

